Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,115 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00560963 | Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine | completed | Phase 1 / Phase 2 | 21 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00715182 | A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer | completed | Phase 1 | 87 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 |
| NCT01263353 | Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(COOPERATE-1) | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01443481 | Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01646684 | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01735968 | A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT02703571 | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | terminated | Phase 1 | 95 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT00093600 | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 69 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT00532389 | Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT01055483 | A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 59 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01242774 | Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01324479 | Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | completed | Phase 1 | 131 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 19, 2020 | clinicaltrials |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | terminated | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01854606 | Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma(COEB071X2103) | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02925104 | A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02988440 | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01456689 | A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02078609 | A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 70 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 17, 2020 | clinicaltrials |
| NCT02144038 | Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 | 2 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02227641 | Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 50 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT01830010 | A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies | completed | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 11, 2020 | clinicaltrials |
| NCT00620594 | A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | completed | Phase 1 | 183 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01223898 | To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01285466 | A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | completed | Phase 1 | 110 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01456676 | Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | completed | Phase 1 | 11 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01613950 | PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01928459 | Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 9, 2020 | clinicaltrials |
| NCT02343172 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | completed | Phase 1 | 74 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT00135005 | Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) | completed | Phase 1 | 59 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT02077933 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 8, 2020 | clinicaltrials |
| NCT02902237 | tTF-NGR Phase I Study | completed | Phase 1 | 24 | University Hospital MuensterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01781572 | A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | completed | Phase 1 / Phase 2 | 102 | PfizerINDUSTRY | 5 | Dec 7, 2020 | clinicaltrials |
| NCT02798978 | A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects | completed | Phase 1 | 42 | GlaxoSmithKlineINDUSTRY | 1 | Nov 27, 2020 | clinicaltrials |
| NCT04195373 | A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract | withdrawn | Phase 1 | 0 | Themis Bioscience GmbHINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT01572519 | A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 2 | Nov 20, 2020 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02308553 | Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma(NIPAWILMA) | completed | Phase 1 / Phase 2 | 33 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02829372 | Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers(GBR 1302-101) | terminated | Phase 1 | 36 | Ichnos Sciences SAINDUSTRY | 2 | Oct 9, 2020 | clinicaltrials |
| NCT01363232 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 89 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 7 | Oct 5, 2020 | clinicaltrials |
| NCT02253992 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 232 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials